Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

15.25 -1.21 (-7.33%)
Streaming Delayed Price Updated: 12:57 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,051,546
Open 15.83
Bid (Size) 15.21 (4)
Ask (Size) 15.26 (2)
Prev. Close 16.46
Today's Range 14.72 - 16.66
52wk Range 16.30 - 35.25
Shares Outstanding 79,199,501
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Via Benzinga
Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock
Via Benzinga

Performance

YTD
-38.2%
-38.2%
1 Month
-42.3%
-42.3%
3 Month
-38.2%
-38.2%
6 Month
-33.5%
-33.5%
1 Year
-48.6%
-48.6%

More News

Read More
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen
Via Benzinga
Analyst Expectations For Beam Therapeutics's Future
Via Benzinga
(BEAM) - Analyzing Beam Therapeutics's Short Interest
Via Benzinga
Demystifying Beam Therapeutics: Insights From 4 Analyst Reviews
Via Benzinga
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity
Via Benzinga
Beam Therapeutics Announces Pricing of Underwritten Offering
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood's Bold Move: 8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14%
Via Benzinga
Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies
Via Benzinga
Cathie Wood's Ark Invest Loads Up On Iridium, Twist Bioscience, Offloads Roku: Here Are Key Ark Trades This Friday
Via Benzinga
Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday
Via Benzinga
Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts
From Beam Therapeutics
Via GlobeNewswire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
Via Investor's Business Daily
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains
Via Benzinga
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
From Beam Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Beam Therapeutics Inc. - Common Stock publicly traded?
Yes, Beam Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Beam Therapeutics Inc. - Common Stock trade on?
Beam Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Beam Therapeutics Inc. - Common Stock?
The ticker symbol for Beam Therapeutics Inc. - Common Stock is BEAM on the Nasdaq Stock Market
What is the current price of Beam Therapeutics Inc. - Common Stock?
The current price of Beam Therapeutics Inc. - Common Stock is 15.25
When was Beam Therapeutics Inc. - Common Stock last traded?
The last trade of Beam Therapeutics Inc. - Common Stock was at 04/04/25 12:57 PM ET
What is the market capitalization of Beam Therapeutics Inc. - Common Stock?
The market capitalization of Beam Therapeutics Inc. - Common Stock is 1.21B
How many shares of Beam Therapeutics Inc. - Common Stock are outstanding?
Beam Therapeutics Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.